| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NASDAQ |
| Div & Yield | N.A. (N.A) |
Latest News
SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Optimer Pharmaceuticals, Inc.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Optimer Pharmaceuticals, Inc.
Investigations Into Proposed Buyouts Of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. And Maidenform Brands, Inc. Announced By Holzer Holzer & Fistel, LLC
Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc.
Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Optimer Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Cubist Pharmaceuticals, Inc.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Optimer Pharmaceuticals...
OPTIMER PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Optimer Pharmaceuticals, Inc. Following Announcement Of Proposed Sale Of Company To Cubist Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr.
OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches Of Fiduciary Duty By Board Of Optimer Pharmaceuticals, Inc. In Connection With Sale Of Company To Cubist Pharmaceuticals, Inc.
Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc.
Milberg Announces Investigation Of Unfair Low Price In Cubist’s Acquisition Of Optimer
Milberg LLP is currently investigating the proposed acquisition of Optimer Pharmaceuticals, Inc.
Rigrodsky & Long, P.A. Announces Investigation Of Optimer Pharmaceuticals, Inc. Buyout
Rigrodsky & Long, P.A.
The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio
Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.
Finkelstein Thompson LLP Announces Investigation Of Optimer Pharmaceuticals, Inc. Buyout
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Optimer Pharmaceuticals, Inc.
Optimer Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Sale Of Optimer To Cubist
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Optimer Pharmaceuticals, Inc.
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Optimer Pharmaceuticals Proposed Acquisition By Cubist Pharmaceuticals, Inc.
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Optimer Pharmaceuticals, Inc.
Comcast, Cubist Jump Pre-market Amid Cautious Trading
Stock futures are little changed Wednesday despite upbeat reports on GDP and jobs ahead of the Fed announcement.
Morning Briefing: 10 Things You Should Know
U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.
SHAREHOLDER ALERT: Wohl & Fruchter Investigating The Acquisition Of Optimer Pharmaceuticals, Inc. By Cubist Pharmaceuticals, Inc.
The law firm of Wohl & Fruchter LLP is investigating the proposed acquisition of Optimer Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches Of Fiduciary Duty By Board Of Optimer Pharmaceuticals, Inc. In Connection With The Sale Of The Company To Cubist Pharmaceuticals, Inc.
Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc.
Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys
Cubist announces two acquisitions in one day.
Cubist Pharmaceuticals To Acquire Optimer Pharmaceuticals
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc.
5 Stocks Poised for Breakouts
These stocks look ready to break out and trade higher from current levels.
Commit To Purchase Optimer Pharmaceuticals At $10, Earn 36.5% Annualized
Investors eyeing a purchase of Optimer Pharmaceuticals Inc shares, but tentative about paying the going market price of $14.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $10 strike, which has a bid at the time of this writing of 30 cents.
Cubist, Optimer, Trius: Antibiotic Deal Making On Tap
The pace of deals among developers of antibiotics is about to ramp higher.
3 Biotech Stocks Spiking With Big Volume
Often when above-average volume moves into an equity, it precedes a large spike in volatility.